Workflow
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
femasysfemasys(US:FEMY) GlobeNewswire News Room·2024-09-03 12:30

Company Overview - Femasys, Inc. is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products [3] - The company has developed products such as FemaSeed® for intratubal insemination and FemBloc® for permanent birth control, which are designed to be safer and more cost-effective alternatives to traditional methods [3] Upcoming Events - Kathy Lee-Sepsick, Founder, President, and CEO of Femasys, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference from September 9 to 11, 2024 [1] - The presentation will be available on-demand starting at 7:00 AM ET on September 9, 2024, and a replay will be archived for approximately 90 days [2] Product Development - FemaSeed® is FDA-cleared and has received regulatory approval in Canada and Europe, while FemBloc® is in late-stage clinical development [3] - The company has achieved regulatory approvals for its diagnostic products, which include FemVue® and FemCerv®, and these products are ready for commercialization due to in-house manufacturing capabilities [3]